肺癌中的抗体药物偶联物：临床试验中的科学突破与未来方向 - Suppr

Antibody-drug conjugates in lung cancer: scientific breakthroughs and future directions in clinical trials.

作者信息

Zhu Qing-Dong, Song Chang, Zhao Chun-Yan, Qiang Hang-Biao, Liu Ren-Hao, Gong Chun-Ming, Tan Qiu-Qing, Jiang Chang-Yue, Yu Mei

机构信息

Department of Tuberculosis, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China.

Guangxi Medical University, Nanning, Guangxi, China.

出版信息

Int J Surg. 2025 Sep 1;111(9):6465-6468. doi: 10.1097/JS9.0000000000002718. Epub 2025 Jun 12.

DOI:10.1097/JS9.0000000000002718

PMID:40503774

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12430769/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ef/12430769/a3b78e48a6ae/js9-111-6465-g001.jpg

相似文献

Antibody-drug conjugates in lung cancer: scientific breakthroughs and future directions in clinical trials.肺癌中的抗体药物偶联物：临床试验中的科学突破与未来方向

Int J Surg. 2025 Sep 1;111(9):6465-6468. doi: 10.1097/JS9.0000000000002718. Epub 2025 Jun 12.

Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions.抗体药物偶联物作为膀胱癌的变革者：当前进展与未来方向

Front Immunol. 2025 May 13;16:1591191. doi: 10.3389/fimmu.2025.1591191. eCollection 2025.

The evolving landscape of antibody-drug conjugates in small cell lung cancer: From research progress to clinical application.小细胞肺癌中抗体药物偶联物的发展态势：从研究进展到临床应用

Biochim Biophys Acta Rev Cancer. 2025 Sep 5;1880(6):189445. doi: 10.1016/j.bbcan.2025.189445.

Aptamer-Drug Conjugates (ApDCs): Transformative approaches in targeted cancer therapy and precision oncology.适体-药物偶联物（ApDCs）：靶向癌症治疗和精准肿瘤学中的变革性方法。

Int J Pharm. 2025 Aug 20;681:125902. doi: 10.1016/j.ijpharm.2025.125902. Epub 2025 Jun 26.

Antibody-oligonucleotide conjugates in cancer therapy: Potential and Promise.癌症治疗中的抗体-寡核苷酸偶联物：潜力与前景。

Crit Rev Oncol Hematol. 2025 Jul 18;215:104858. doi: 10.1016/j.critrevonc.2025.104858.

Theranostic antibody conjugates: A review of recent trends and applications in cancer.诊疗性抗体偶联物：癌症领域近期趋势与应用综述

Bioorg Chem. 2025 Sep;164:108915. doi: 10.1016/j.bioorg.2025.108915. Epub 2025 Aug 25.

An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer.达泊妥单抗德鲁替康治疗非小细胞肺癌的评估。

Expert Opin Biol Ther. 2025 Jul;25(7):695-701. doi: 10.1080/14712598.2025.2519532. Epub 2025 Jun 15.

A New Era in Tuberculosis Prevention and Treatment: Breakthroughs in Drug Development and Future Prospects.结核病预防与治疗的新时代：药物研发的突破与未来前景

Infect Dis Ther. 2025 Sep 3. doi: 10.1007/s40121-025-01221-3.

TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).TROP-2 定向抗体药物偶联物（ADC）：在晚期非小细胞肺癌（NSCLC）中智能药物递送的革命。

Cancer Treat Rev. 2023 Jul;118:102572. doi: 10.1016/j.ctrv.2023.102572. Epub 2023 May 19.

The tricky effects of TROP2 in lung cancer: from clinical practice back to fundamental investigations.TROP2在肺癌中的复杂作用：从临床实践回归基础研究

Front Oncol. 2025 Aug 22;15:1638054. doi: 10.3389/fonc.2025.1638054. eCollection 2025.

本文引用的文献

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.赛托珠单抗妥昔单抗用于治疗伴有或不伴有EGFR突变的晚期非小细胞肺癌：1/2期和2期试验

Nat Med. 2025 Apr 10. doi: 10.1038/s41591-025-03638-2.

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.达泊托单抗德卢替康与多西他赛用于既往治疗过的晚期或转移性非小细胞肺癌：随机、开放标签的III期TROPION-Lung01研究

J Clin Oncol. 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. Epub 2024 Sep 9.

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.Sacituzumab Govitecan 与多西他赛治疗既往治疗的晚期或转移性非小细胞肺癌：随机、开放标签 III 期 EVOKE-01 研究。

J Clin Oncol. 2024 Aug 20;42(24):2860-2872. doi: 10.1200/JCO.24.00733. Epub 2024 May 31.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康用于转移性非小细胞肺癌患者（DESTINY-Lung01）：一项单臂、2 期临床试验中 HER2 过表达队列的主要结果。

Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.

Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.利用 Trop2 抗体药物偶联物治疗实体瘤。

Annu Rev Med. 2024 Jan 29;75:31-48. doi: 10.1146/annurev-med-071322-065903. Epub 2023 Sep 27.

Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.抗体偶联药物治疗肺癌：有效载荷与进展。

Am Soc Clin Oncol Educ Book. 2023 May;43:e389968. doi: 10.1200/EDBK_389968.

Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.靶向肺癌中TROP-2的抗体药物偶联物（ADC）

Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1077-1087. doi: 10.1080/14712598.2023.2198087. Epub 2023 Apr 3.

Antibody Drug Conjugates in Lung Cancer.肺癌中的抗体药物偶联物

Cancer J. 2022;28(6):429-435. doi: 10.1097/PPO.0000000000000630.

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.抗体药物偶联物：肺癌治疗的新希望

Lung Cancer. 2022 Jan;163:96-106. doi: 10.1016/j.lungcan.2021.12.002. Epub 2021 Dec 15.

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.与拓扑替康相比，罗伐匹妥珠单抗替西瑞林作为DLL3高表达小细胞肺癌二线治疗的疗效和安全性：3期TAHOE研究结果

J Thorac Oncol. 2021 Sep;16(9):1547-1558. doi: 10.1016/j.jtho.2021.02.009. Epub 2021 Feb 16.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody-drug conjugates in lung cancer: scientific breakthroughs and future directions in clinical trials.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献